Rather than talk in theory, Richard works through each route the way he assesses deals for clients every week. He covers the pros and cons of each, what separates a deal worth doing from one to walk away from, and the points where investors most often lose money before they have even started. Then he answers the two questions everyone brings to this decision: which one would he choose, and which one is right for you.

For the market heading into 2026 and 2027, this is the session to sit in. Less new stock is being created, the days of buying an HMO as a get-rich strategy have gone, and the value now sits with buyers who can read a deal properly. The call gives that reading, from someone who assesses and consults on dozens of these deals a month.

There will be plenty of people across the network toying between options 1, 2 and 3. This is the chance to have those deals broken down in the room, and to bring your own for the same treatment.